3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Uterine Cervical Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Ovarian Neoplasms
1
Osteosarcoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
1
Chondrosarcoma
1
Interventions
Doxorubicin
3
spartalizumab
1
nilotinib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
envafolimab
1
Trabectedin
1
TQ-B3525
1
Radiotherapy
1
Proton Therapy
1
Nivolumab
1
Neoadjuvant Therapy
1
Ipilimumab
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
Heavy Ion Radiotherapy
1
Gelclair
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Chondrosarcoma
×
TQ-B3525
×
Clear all
NCT04690725
2020-12-31
TQBSP
Peking University People's Hospital
Phase 1/2
Unknown
29 enrolled